Resultados da busca - Mark Hyman Rapaport
- Mostrando 1 - 20 resultados de 32
- Ir para a próxima página
-
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study por Mark Hyman Rapaport, Andrew A. Nierenberg, Pamela J. Schettler, Becky Kinkead, Amber Cardoos, Rosemary Walker, David Mischoulon
Publicado em 2015Artigo -
10
-
11
Treating Major Depression by Creating Positive Expectations for the Future: A Pilot Study for the Effectiveness of Future‐Directed Therapy (FDT) on Symptom Severity and Quality of... por Jennice Vilhauer, Sabrina Young, Chanel Kealoha, Josefine Borrmann, Waguih William IsHak, Mark Hyman Rapaport, Narineh Hartoonian, Jim Mirocha
Publicado em 2011Artigo -
12
-
13
Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Stud... por C.E.M. Griffiths, Maurizio Fava, Andrew H. Miller, James Russell, Susan Ball, Wen Xu, Nayan Acharya, Mark Hyman Rapaport
Publicado em 2017Artigo -
14
Deficits in Psychological Well‐Being and Quality‐of‐Life in Minor Depression: Implications for DSM‐V por Andrew A. Nierenberg, Mark Hyman Rapaport, Pamela J. Schettler, Robert H. Howland, Juliana A. Smith, Deidre Edwards, Trisha Schneider, David Mischoulon
Publicado em 2010Artigo -
15
-
16
Clinical response to EPA supplementation in patients with major depressive disorder is associated with higher plasma concentrations of pro-resolving lipid mediators por Stefania Lamon‐Fava, Minying Liu, Boadie W. Dunlop, Becky Kinkead, Pamela J. Schettler, Jennifer C. Felger, Thomas R. Ziegler, Maurizio Fava, David Mischoulon, Mark Hyman Rapaport
Publicado em 2023Artigo -
17
Effects of Risperidone Augmentation in Patients with Treatment-Resistant Depression: Results of Open-Label Treatment Followed by Double-Blind Continuation por Mark Hyman Rapaport, Georges M. Gharabawi, Carla M. Canuso, Ramy Mahmoud, Martin B. Keller, Cynthia A. Bossie, Ibrahim Turkoz, Robert Lasser, Amy Loescher, Philippe Bouhours, Fiona Dunbar, Charles B. Nemeroff
Publicado em 2006Artigo -
18
Application of Noninvasive Vagal Nerve Stimulation to Stress-Related Psychiatric Disorders por J. Douglas Bremner, Nil Z. Gurel, Matthew T. Wittbrodt, Md Mobashir Hasan Shandhi, Mark Hyman Rapaport, Jonathon A. Nye, Bradley D. Pearce, Viola Vaccarino, Amit Shah, Jeanie Park, Marom Bikson, Omer T. Inan
Publicado em 2020Revisão -
19
Dose- and time-dependent increase in circulating anti-inflammatory and pro-resolving lipid mediators following eicosapentaenoic acid supplementation in patients with major depressi... por Stefania Lamon‐Fava, Jisun So, David Mischoulon, Thomas R. Ziegler, Boadie W. Dunlop, Becky Kinkead, Pamela J. Schettler, Andrew A. Nierenberg, Jennifer C. Felger, Krishna Rao Maddipati, Maurizio Fava, Mark Hyman Rapaport
Publicado em 2020Artigo -
20
Massage therapy decreases cancer-related fatigue: Results from a randomized early phase trial por Becky Kinkead, Pamela J. Schettler, Erika R. Larson, Dedric Carroll, Margaret Sharenko, James H. Nettles, Sherry A. Edwards, Andrew H. Miller, Mylin A. Torres, Boadie W. Dunlop, Jeffrey J. Rakofsky, Mark Hyman Rapaport
Publicado em 2017Artigo
Ferramentas de busca:
Assuntos relacionados
Medicine
Psychiatry
Psychology
Internal medicine
Biology
Pathology
Alternative medicine
Schizophrenia (object-oriented programming)
Depression (economics)
Economics
Macroeconomics
Major depressive disorder
Gene
Genetics
Clinical psychology
Mood
Placebo
Bipolar disorder
Environmental health
Genotype
Single-nucleotide polymorphism
Genome-wide association study
Population
Psychosis
Randomized controlled trial
Amygdala
Anxiety
Biochemistry
Cognition
Eicosapentaenoic acid